- Home
- IEP vs DNTH Comparison
IEP vs DNTH Comparison
Compare IEP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEP | DNTH |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.6B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IEP | DNTH |
|---|---|---|
| Price | $7.41 | $83.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.0M | 528.1K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 24.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,658,000,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.02 | $29.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.08 | $16.77 |
| 52 Week High | $9.75 | $96.50 |
Technical Indicators
Market Signals| Indicator | IEP | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 37.02 | 45.68 |
| Support Level | $7.08 | $79.27 |
| Resistance Level | $8.25 | $91.04 |
| Average True Range (ATR) | 0.10 | 4.76 |
| MACD | -0.01 | -0.74 |
| Stochastic Oscillator | 15.91 | 32.85 |
Price Performance
Historical ComparisonAbout IEP Icahn Enterprises L.P.
Icahn Enterprises LP provides diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.